Highlights Merck & Co., Inc.

Equities

MRK

US58933Y1055

Market Closed - Nyse Other stock markets 16:00:31 2024-09-06 EDT			5-day change	1st Jan Change
117.84 ^USD	-0.63%		-0.51%	+8.09%

09-06	Veeva Systems: leader in cloud solutions for the life sciences industry
09-05	US Equities Markets End Mixed Thursday as Investors Evaluate Job Growth Report	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

US Equities Markets End Mixed Thursday as Investors Evaluate Job Growth Report	09-05	MT
Sector Update: Health Care Stocks Fall Late Afternoon	09-05	MT
Sector Update: Health Care Stocks Slide Thursday Afternoon	09-05	MT
US Equity Indexes Mixed as Investors Eye Friday's Nonfarm Payrolls After Private Jobs Unexpectedly Slow Down	09-05	MT
Merck Completes Negotiations With Pan-Canadian Pharma Alliance	09-05	MT
Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension	09-04	CI
Merck to present advances in oncology	09-04	CF
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024	09-04	CI
Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret?? for the Treatment of Diabetic Macular Edema	09-04	CI
Merck: EU approves urothelial carcinoma treatment	09-03	CF
European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults	09-03	CI
US will still pay at least twice as much after negotiating drug prices	09-03	RE
IO Biotech Gets Data Monitoring Committee Recommendation to Continue Phase 3 Melanoma Study	08-30	MT
Merck to Discontinue 2 Phase 3 Trials on Keytruda	08-29	MT
Merck: terminates two phase III trials on Keytruda	08-29	CF
Merck Discontinuing Phase 3 Trials of Keytruda in Non-Small Cell Lung Cancer, Skin Cancer	08-29	MT
Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials	08-29	CI
Citic Securities Initiates Merck & Co. at Buy With $136 Price Target	08-29	MT
Nvidia results could spur record $300 billion swing in shares, options show	08-27	RE
Merck Initiates Phase 3 Trial to Evaluate Essential Thrombocythemia Treatment Candidate	08-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Merck & Co., Inc.

Equities

MRK

US58933Y1055

Highlights

Filters